BBIO Earnings Bridgebio Pharma, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -0.84 | 2026-05-07 | 10-Q |
| FY 2025 | 2025-12-31 | -3.78 | 2026-02-24 | 10-K |
| Q3 2025 | 2025-09-30 | -2.79 | 2025-10-29 | 10-Q |
| Q2 2025 | 2025-06-30 | -1.84 | 2025-08-05 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.88 | 2026-05-07 | 10-Q |
| FY 2025 | 2024-12-31 | -2.88 | 2026-02-24 | 10-K |
| Q3 2025 | 2024-09-30 | -1.46 | 2025-10-29 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.59 | 2025-08-05 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.20 | 2025-04-29 | 10-Q |
| FY 2025 | 2023-12-31 | -3.95 | 2026-02-24 | 10-K |
| Q3 2024 | 2023-09-30 | -2.99 | 2024-11-12 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.90 | 2024-08-01 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.92 | 2024-05-02 | 10-Q |
| FY 2024 | 2022-12-31 | -3.26 | 2025-02-20 | 10-K |
| Q3 2023 | 2022-09-30 | -2.34 | 2023-11-02 | 10-Q |
| Q2 2023 | 2022-06-30 | -1.41 | 2023-08-03 | 10-Q |
| Q1 2023 | 2022-03-31 | -1.35 | 2023-05-04 | 10-Q |
| FY 2023 | 2021-12-31 | -3.90 | 2024-02-22 | 10-K |
| Q3 2022 | 2021-09-30 | -2.88 | 2022-11-03 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.82 | 2022-08-04 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.